Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2020 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress

Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma IND Cleared for...
August 04, 2020 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
July 29, 2020 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
July 14, 2020 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies

License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients Preclinical Data Published in the Journal Nature...
July 09, 2020 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy

FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819 for Patients with...
June 11, 2020 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
June 09, 2020 00:49 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
June 08, 2020 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
May 20, 2020 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma Off-the-shelf...
May 11, 2020 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress

Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates First Patient Treated with FT596, the First-ever Cellular Immunotherapy Engineered with...